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What is Kawasaki Disease?
Kawasaki Disease (KD) is an acute 
febrile illness that can potentially af-
fect the heart and its larger arteries. It 
often affects children younger than five 
years.1 KD is also called mucocutane-
ous lymph node syndrome, because it 
involves lymph nodes, skin, and mucous 
membranes inside the mouth, nose, and 
throat.1,2 According to the American Heart 
Association3 and the Centers for Disease 
Control and Prevention,1 KD diagnostic 
criteria include high fever lasting four or 
five days, along with four or more of the 
following seven symptoms: 1) rash, 2) red 
eyes, 3) red, swollen, and cracked lips, 
4) “strawberry” tongue, 5) swollen hands 
and feet, 6) swollen lymph nodes, and 7) 
redness of the palms and soles of the feet.
Statistics and Recent Trends
In the US alone, about 5500 cases of 
KD were estimated in 2009.1 In Japan, 
a 2008 nationwide study conducted by 
Nakamura et al4 found that 19,138 patients 
were suffering from KD during the 2-year 
period 2003–2004, revealing the continu-
ation of an upward trend that started in 
Japan in the mid-1990s. A survey in 2009 
suggested that the incidence is also rising 
in India.5 This may be explained by greater 
awareness or by rapid industrialization.6 
The latest incidence statistics available 
for the US are from a 2010 retrospective 
national study by Holman et al7: the rate of 
hospitalization related to KD in 2006 was 
20.8 per 100,000 children younger than 
age 5 years. It is more frequent in children 
older than 1 year and toddlers ages 1 to 4 
years. KD affects all ethnicities and races, 
but it is most common among children of 
Asian and Pacific Islander descent, with 
30.3 cases per 100,000 hospitalizations. 
The incidence for non-Hispanic Blacks, 
non-Hispanic Whites, and Hispanics is 
17.5, 12, and 15.7 cases per 100,000 hos-
pitalizations, respectively.7 
KD is the leading cause of acquired 
cardiovascular disease in children in the 
US.8 The etiology of KD remains unknown 
after 40 years of intense research,9 and no 
laboratory test can accurately diagnose 
KD and atypical cases that are approxi-
mate KD but do not meet all diagnostic 
criteria for KD.1 Delayed diagnosis and 
treatment remain prevalent and unavoid-
able.10 Diagnosis is further complicated in 
that KD shares symptoms and signs with 
other illnesses.2 Therefore, the real num-
ber of undertreated and misdiagnosed 
cases is unknown.11
Diagnosis and Etiology
Virtually all deaths in patients who 
have experienced KD result from cardiac 
sequelae, or secondary cardiac conditions 
such as arrhythmia, chest pain, myocardial 
infarction (MI), and sudden death.12,13
Mortality peaks 15 to 45 days after the 
initial onset of fever. However, sudden 
death from MI may occur many years 
later in individuals who had coronary 
artery aneurysms (CAA) and stenoses as 
children. The potential for death years 
later because of KD complications sug-
gests that it is important to follow KD 
patients throughout childhood. Many 
cases of fatal and nonfatal MIs in young 
adults have been attributed to “missed” 
KD in childhood.12 
A recent study by Coustasse and associ-
ates10 revealed that fewer than half of the 
patients in their Texas sample (n = 303) 
were correctly diagnosed with KD upon 
hospital admission. The majority of KD 
cases were misdiagnosed. In their cross-
sectional analysis, there were 41 admit-
ting diagnoses other than KD. Although 
misdiagnosis appears to be common, the 
overwhelming majority (> 96%) of children 
with KD are hospitalized.14,15 The remain-
ing 4% are treated on an outpatient basis. 
Untreated, KD can lead to serious com-
plications that involve the heart and car-
diovascular system.2 Because CAA occurs 
more frequently in untreated patients,16
effective interventions are required to 
enhance clinicians’ ability to accurately 
identify KD in children younger than age 
5 years presenting with high fever and 
rash.17 Treatment within 10 days after 
onset of fever is essential to decrease the 
risk of heart problems. With appropriate 
detection and treatment, the prevalence 
of CAA is reduced to as few as 1% and 
no more than 5% of cases.18
The Lloyd et al study19 investigated 
clinical and epidemiologic features of 
KD and emphasized the likelihood of an 
infectious cause. Consequently, several 
microbial agents have been studied in 
connection with KD: Rickettsiae, Propioni-
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Abstract
Kawasaki Disease (KD) is the leading cause of acquired cardiovascular disease 
among children, but management of KD has received relatively little attention. In the 
US alone, about 5500 cases were estimated in 2009. KD is most common among 
Asian and Pacific Islander children but can affect all ethnicities and races. Timely 
and accurate diagnosis remains critical, but difficult: the etiology of KD is unknown, 
and no accurate diagnostic laboratory test has been developed. Continuing medical 
education can help physicians, clinicians, and nurse practitioners accurately diagnose 
and treat KD. A registry specific to KD or a surveillance system may be necessary to 
increase awareness among health care professionals and to decrease complications 
related to misdiagnosis.
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bacterium acnes, Klebsiella pneumoniae, 
Ehrlichia, parainfluenza virus types 2 
and 3, Epstein-Barr virus, and rotavirus, 
among others.20,21 Additional possible 
causes for the disease are prior respira-
tory disease; exposure to carpet cleaning 
chemicals; use of humidifiers; and living 
in close proximity to lakes, rivers, bays, 
or oceans.8,22 Although multiple infectious 
agents and toxins have been implicated, 
none have been conclusively identified as 
a causative or contributing agent.15
Treatment
First-line treatment consists of intrave-
nous immunoglobulin for 8 hours to 12 
hours within 10 days of the first onset 
of fever. High doses of aspirin must be 
administered until the fever subsides. 
Aspirin should be continued and gradu-
ally tapered for at least 2 months to re-
duce the risk of spontaneous coronary 
thrombosis.2,18 A substantial number of 
patients have an incomplete response 
to intravenous immunoglobulin and 
require additional treatment. Unrespon-
sive patients are at high risk of coronary 
abnormalities and adverse events result-
ing from multiple therapies.23 In 13% 
to 30% of KD patients, fever persists or 
recurs. Fever may recur several days after 
hospital discharge. Doctors must bear 
the responsibility of warning parents to 
return to the hospital if fever or other 
signs of KD recur; inadequate discharge 
instructions put patients at risk for de-
veloping coronary artery abnormalities.24
Untreated recurrences can lead to aneu-
rism of the coronary arteries, myocardi-
tis,25 toxic shock,26 and sudden death.27
Sudden death from MI can occur many 
years later in individuals who developed 
CAA and stenoses in childhood.28 
Ongoing Surveillance
Developing and maintaining a KD-spe-
cific national registry or a KD surveillance 
system may help reduce the nationwide 
incidence of KD. National and state in-
cidence is difficult to estimate, because 
reporting of KD cases to the Centers for 
Disease Control and Prevention remains 
sporadic,9 and all tracking and reporting 
is left to state agencies to enforce.29 As 
with any large passive surveillance sys-
tem, only a fraction of cases is reported.22
Researchers are forced to rely on hospital 
discharge data.15 The central public health 
policy problems related to KD are the 
need to educate clinicians, and the need 
for a government policy ensuring the 
timely acquisition of accurate data for all 
suspected KD cases for purposes of early 
diagnosis, patient tracking, and determin-
ing the cause of the disease.10 
Continuing Medical 
Education
Although KD is now the leading cause 
of acquired heart disease among children 
in developed countries,30 its etiology re-
mains unknown. To diagnose KD early 
and accurately, clinicians must be educated 
to recognize the signs and symptoms of 
KD and make differential diagnoses. This 
training should begin in medical schools 
and continue through continuing medical 
education courses. Pediatricians, emer-
gency medicine physicians, and primary 
care physicians must stay abreast of the 
latest developments in pediatric medicine 
and infectious diseases. Continuing medi-
cal education has become increasingly 
important to the management of KD be-
cause of the serious and sometimes fatal 
consequences of delayed treatment caused 
by erroneous diagnoses. If professional as-
sociations and state licensure boards were 
to require KD-specific education, perhaps 
the national rate of misdiagnosis could be 
significantly reduced.
Conclusion
Because KD is the leading cause of 
acquired heart disease among children in 
the US, and considering the sudden deaths 
that result from coronary aneurysm and 
thrombosis, effective management of KD 
would substantially benefit public health.8 
It is imperative to educate physicians 
and other clinicians, including nurses, to 
recognize the signs and symptoms of KD, 
because delayed or erroneous diagnoses 
delay treatment and sometimes lead to 
death. This also hinders cost contain-
ment efforts at the national level. Active 
surveillance could potentially yield long-
term benefits for clinicians, patients, and 
society as a whole by facilitating the 
identification, prevention, and treatment 
of KD. The financial costs and benefits of 
accurate diagnosis and treatment may be 
further quantifiable when more accurate 
data are available. v
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The Principle of Life
Since all living things are warm, all dying things cold,  
there must be a … seat and fountain,  
a kind of home and hearth, where the cherisher of nature,  
the original of the native fire, is stored and preserved;  
from which heat and life are dispensed to all parts as from a fountain head;  
from which sustenance may be derived; and upon which concoction and nutrition,  
and all vegetative energy may depend. Now that the heart is this place,  
that the heart is the principle of life … I trust no one will deny.
— On Circulation of the Blood, William Harvey, 1578 – 1657, English physician and first person to describe completely 
and in detail the systemic circulation and properties of blood being pumped through the body by the heart
